Home Cart Sign in  
Chemical Structure| 396129-53-6 Chemical Structure| 396129-53-6

Structure of LY364947
CAS No.: 396129-53-6

Chemical Structure| 396129-53-6

LY364947

CAS No.: 396129-53-6

LY-364947 (HTS466284) displays potent ATP-competitive inhibition of TGFβR-I with an IC50 of 59 nM and exhibits 7-fold selectivity over TGFβR-II.

4.5 *For Research Use Only !

Cat. No.: A131713 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÇǶÊÊ Inquiry Inquiry
5mg łÇÿ¶ÊÊ Inquiry Inquiry
10mg łÇó¶ÊÊ Inquiry Inquiry
50mg łòʶÊÊ Inquiry Inquiry
100mg łÇʧ¶ÊÊ Inquiry Inquiry
250mg łÇóò¶ÊÊ Inquiry Inquiry
1g łÿÊ˶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • 1mg

    łÇǶÊÊ

  • 5mg

    łÇÿ¶ÊÊ

  • 10mg

    łÇó¶ÊÊ

  • 50mg

    łòʶÊÊ

  • 100mg

    łÇʧ¶ÊÊ

  • 250mg

    łÇóò¶ÊÊ

  • 1g

    łÿÊ˶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LY364947

CAS No. :396129-53-6
Formula : C17H12N4
M.W : 272.30
SMILES Code : C1(C2=CNN=C2C3=NC=CC=C3)=CC=NC4=CC=CC=C14
MDL No. :MFCD00800758
InChI Key :IBCXZJCWDGCXQT-UHFFFAOYSA-N
Pubchem ID :447966

Safety of LY364947

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • CK1

    CK1δ, IC50:0.22 μM

  • TGFβRII

    TGFβRII, IC50:0.4 μM

  • TGFβRI/ALK5

    TGFβRI, IC50:59 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
SW480 cells 5 μmol/L 48 hours To investigate the effect of LY364947 on Smad4-mediated inhibition of claudin-1 expression, results showed that LY364947 did not prevent Smad4 from inhibiting claudin-1 expression. PMC6574217
HT29 cells 5 μmol/L 72 hours To investigate the effect of LY364947 on Smad4-mediated inhibition of claudin-1 expression, results showed that LY364947 did not prevent Smad4 from inhibiting claudin-1 expression. PMC6574217
Human microvascular endothelial cells (HDME) 2 ng/mL 3 hours To study the effect of TGF-β on vascular endothelial cells PMC3878438
Human smooth muscle cells (HSM) 1 µM 3 hours To study the effect of TGF βi-MSNP on the interaction between smooth muscle cells and endothelial cells PMC3878438
GL261 400 nM 24 hours LY364947 significantly increased the radiosensitivity of GL261, U251, and U87MG cells, and reduced radiation-induced ATM and p53 phosphorylation. PMC3538149
U251 400 nM 24 hours LY364947 significantly increased the radiosensitivity of GL261, U251, and U87MG cells, and reduced radiation-induced ATM and p53 phosphorylation. PMC3538149
U87MG 400 nM 24 hours LY364947 significantly increased the radiosensitivity of GL261, U251, and U87MG cells, and reduced radiation-induced ATM and p53 phosphorylation. PMC3538149
4T1 cells 50 μg/mL 24 hours To evaluate the cytotoxicity of LY364947 on 4T1 cells in vitro and its ability to induce cell death. The results showed that LY364947 significantly induced cell death under ultrasound irradiation, especially after DAC pretreatment, with a cell death rate of 76%. PMC9513558

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice BxPC3 tumor xenograft model Intravenous injection 50 mg/kg once a day for five consecutive days, then suspended for 2 days, for 4 weeks To study the therapeutic effect of TGF βi-MSNP on BxPC3 tumor xenografts PMC3878438
C57/BL6 mice GL261 flank tumor model intraperitoneal injection 50 mg/kg daily for 8 days 1D11 antibody significantly increased tumor growth delay and reduced radiation-induced γH2AX foci. PMC3538149
BALB/c mice 4T1 breast cancer model Intravenous injection 1 mg/kg Every 3–6 days for 38 days To evaluate the anti-tumor effect of LY364947 in vivo and its modulation of the tumor microenvironment. The results showed that LY364947 combined with ultrasound irradiation significantly inhibited tumor growth and almost completely eliminated the tumor after DAC pretreatment. In addition, LY364947 enhanced T-lymphocyte infiltration through collagen depletion, further amplifying the pyroptosis-mediated tumor immunotherapy effect. PMC10086211

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.67mL

0.73mL

0.37mL

18.36mL

3.67mL

1.84mL

36.72mL

7.34mL

3.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories